Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy

References

• Nagaprashantha L, Vartak N, Awasthi S, Awasthi S, Singhal SS. Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors. Pharm Res 2012; 29:621 - 36; http://dx.doi.org/10.1007/s11095-011-0645-9; PMID: 22203324
   PubMed Web of Science ®Google Scholar
• Mailleux AA, Overholtzer M, Schmelzle T, Bouillet P, Strasser A, Brugge JS. BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms. Dev Cell 2007; 12:221 - 34; http://dx.doi.org/10.1016/j.devcel.2006.12.003; PMID: 17276340
   PubMed Web of Science ®Google Scholar
• Schmelzle T, Mailleux AA, Overholtzer M, Carroll JS, Solimini NL, Lightcap ES, Veiby OP, Brugge JS. Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci U S A 2007; 104:3787 - 92; http://dx.doi.org/10.1073/pnas.0700115104; PMID: 17360431
   PubMed Web of Science ®Google Scholar
• Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell 2008; 19:797 - 806; http://dx.doi.org/10.1091/mbc.E07-10-1092; PMID: 18094039
   PubMed Web of Science ®Google Scholar
• Whelan KA, Caldwell SA, Shahriari KS, Jackson SR, Franchetti LD, Johannes GJ, Reginato MJ. Hypoxia suppression of Bim and Bmf blocks anoikis and luminal clearing during mammary morphogenesis. Mol Biol Cell 2010; 21:3829 - 37; http://dx.doi.org/10.1091/mbc.E10-04-0353; PMID: 20861305
   PubMed Web of Science ®Google Scholar
• Zhong X, Rescorla FJ. Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell Signal 2012; 24:393 - 401; http://dx.doi.org/10.1016/j.cellsig.2011.10.005; PMID: 22024283
   PubMed Web of Science ®Google Scholar
• Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev 2012; 31:397 - 414; http://dx.doi.org/10.1007/s10555-012-9351-2; PMID: 22527451
   PubMed Web of Science ®Google Scholar
• Beauséjour M, Noël D, Thibodeau S, Bouchard V, Harnois C, Beaulieu JF, Demers MJ, Vachon PH. Integrin/Fak/Src-mediated regulation of cell survival and anoikis in human intestinal epithelial crypt cells: selective engagement and roles of PI3-K isoform complexes. Apoptosis 2012; 17:566 - 78; http://dx.doi.org/10.1007/s10495-012-0713-6; PMID: 22402981
   PubMed Web of Science ®Google Scholar
• Haenssen KK, Caldwell SA, Shahriari KS, Jackson SR, Whelan KA, Klein-Szanto AJ, Reginato MJ. ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells. J Cell Sci 2010; 123:1373 - 82; http://dx.doi.org/10.1242/jcs.050906; PMID: 20332114
   PubMed Web of Science ®Google Scholar
• Zheng Y, Gierut J, Wang Z, Miao J, Asara JM, Tyner AL. Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. Oncogene 2012; PMID: 23027128
   PubMed Web of Science ®Google Scholar
• Atadja PW. HDAC inhibitors and cancer therapy. Prog Drug Res 2011; 67:175 - 95; PMID: 21141730
   PubMedGoogle Scholar
• Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem 2012; 4:1439 - 60; http://dx.doi.org/10.4155/fmc.12.80; PMID: 22857533
   PubMed Web of Science ®Google Scholar
• Lee JH, Choy ML, Marks PA. Mechanisms of resistance to histone deacetylase inhibitors. Adv Cancer Res 2012; 116:39 - 86; PMID: 23088868
   PubMed Web of Science ®Google Scholar
• Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2012; 31:537 - 51; PMID: 21725353
   PubMed Web of Science ®Google Scholar
• Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, Reinehr R, Larner A, Spiegel S, Fisher PB, et al. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res 2010; 70:6313 - 24; http://dx.doi.org/10.1158/0008-5472.CAN-10-0999; PMID: 20631069
   PubMed Web of Science ®Google Scholar
• Rosato RR, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S, Dent P, Grant S. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol 2006; 69:216 - 25; PMID: 16189296
   PubMed Web of Science ®Google Scholar
• Cruickshanks N, Hamed HA, Bareford MD, Poklepovic A, Fisher PB, Grant S, Dent P. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Mol Pharmacol 2012; 81:748 - 58; http://dx.doi.org/10.1124/mol.112.077586; PMID: 22357666
   PubMed Web of Science ®Google Scholar
• Cruickshanks N, Tang Y, Booth L, Hamed H, Grant S, Dent P. Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress. Mol Pharmacol 2012; 82:1217 - 29; http://dx.doi.org/10.1124/mol.112.081539; PMID: 22989520
   PubMed Web of Science ®Google Scholar
• Tang Y, Hamed HA, Cruickshanks N, Fisher PB, Grant S, Dent P. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Mol Pharmacol 2012; 81:527 - 40; http://dx.doi.org/10.1124/mol.111.076851; PMID: 22219388
   PubMed Web of Science ®Google Scholar
• Smith MA, Houghton P. A proposal regarding reporting of in vitro testing results. Clin Cancer Res 2013; 19:2828 - 33; http://dx.doi.org/10.1158/1078-0432.CCR-13-0043; PMID: 23580781
   PubMed Web of Science ®Google Scholar
• Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R, Willis F, Burny A, Lagneaux L, Bron D, et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 2009; 144:41 - 52; http://dx.doi.org/10.1111/j.1365-2141.2008.07426.x; PMID: 19006566
   PubMed Web of Science ®Google Scholar
• Pompeia C, Hodge DR, Plass C, Wu YZ, Marquez VE, Kelley JA, Farrar WL. Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res 2004; 64:3465 - 73; http://dx.doi.org/10.1158/0008-5472.CAN-03-3970; PMID: 15150099
   PubMed Web of Science ®Google Scholar
• Premkumar DR, Jane EP, Agostino NR, DiDomenico JD, Pollack IF. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol Carcinog 2013; 52:118 - 33; http://dx.doi.org/10.1002/mc.21835; PMID: 22086447
   PubMed Web of Science ®Google Scholar
• Barbone D, Cheung P, Battula S, Busacca S, Gray SG, Longley DB, Bueno R, Sugarbaker DJ, Fennell DA, Broaddus VC. Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PLoS One 2012; 7:e52753; http://dx.doi.org/10.1371/journal.pone.0052753; PMID: 23300762
   PubMed Web of Science ®Google Scholar
• Feng L, Pan M, Sun J, Lu H, Shen Q, Zhang S, Jiang T, Liu L, Jin W, Chen Y, et al. Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells. J Mol Med (Berl) 2013; 91:49 - 58; http://dx.doi.org/10.1007/s00109-012-0932-x; PMID: 22763818
   PubMed Web of Science ®Google Scholar
• Fritsche P, Seidler B, Schüler S, Schnieke A, Göttlicher M, Schmid RM, Saur D, Schneider G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009; 58:1399 - 409; http://dx.doi.org/10.1136/gut.2009.180711; PMID: 19528037
   PubMed Web of Science ®Google Scholar
• Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, Park MA, Yacoub A, Fisher PB, et al. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Mol Pharmacol 2008; 74:807 - 22; http://dx.doi.org/10.1124/mol.108.047365; PMID: 18544666
   PubMed Web of Science ®Google Scholar
• Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther 2009; 8:2084 - 96; http://dx.doi.org/10.4161/cbt.8.21.9895; PMID: 19823038
   PubMed Web of Science ®Google Scholar
• Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, Yang C, Nephew KP, Dent P. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 2010; 10:903 - 17; http://dx.doi.org/10.4161/cbt.10.9.13273; PMID: 20855960
   PubMed Web of Science ®Google Scholar
• Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, Siu LL, Berger MS, Viallet J, Marshall JL. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 2010; 16:4038 - 45; http://dx.doi.org/10.1158/1078-0432.CCR-10-0822; PMID: 20538761
   PubMed Web of Science ®Google Scholar
• Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, Chu QS, Ross HJ, Subramaniam DS, Schnyder J, et al. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer 2012; 106:839 - 45; http://dx.doi.org/10.1038/bjc.2012.21; PMID: 22333598
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009; 113:299 - 305; http://dx.doi.org/10.1182/blood-2008-02-137943; PMID: 18931344
   PubMed Web of Science ®Google Scholar
• Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, et al. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 2010; 66:1079 - 85; http://dx.doi.org/10.1007/s00280-010-1265-5; PMID: 20165849
   PubMed Web of Science ®Google Scholar
• Parikh SA, Kantarjian H, Schimmer A, Walsh W, Asatiani E, El-Shami K, Winton E, Verstovsek S. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk 2010; 10:285 - 9; http://dx.doi.org/10.3816/CLML.2010.n.059; PMID: 20709666
   PubMed Web of Science ®Google Scholar
• Schimmer AD, O’Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:8295 - 301; http://dx.doi.org/10.1158/1078-0432.CCR-08-0999; PMID: 19088047
   PubMed Web of Science ®Google Scholar